97. 潰瘍性大腸炎 [臨床試験数:2,269,薬物数:1,331(DrugBank:241),標的遺伝子数:114,標的パスウェイ数:181

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
16 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN0000300002018/02/0701/12/2017The efficacy and safety of topical budezonide for pouchitis after restorative proctocolectomy in patients with ulcerative colitis.The efficacy and safety of topical budezonide for pouchitis after restorative proctocolectomy in patients with ulcerative colitis. - The efficacy and safety of topical budezonide for pouchitis. ulcerative colitispouchitisTopical budesonido
2weeks of 2mg daily
Topical prednisolone
2weeks 20mg daily
Topical aminosalicylate
2weeks 1g daily
Department of Inflammatory Bowel DiseaseHyogo College of MedicineNULLRecruitingNot applicableNot applicableMale and Female30Phase 1Japan
2NCT02425852December 201621/4/2015A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe ColitisA Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe ColitisUlcerative ColitisDrug: Azathioprine;Drug: Infliximab;Drug: Prednisolone;Drug: HydrocortisoneGroupe d'Etude Therapeutique des Affections Inflammatoires DigestivesNULLRecruiting18 YearsN/AAll146Phase 4France
3EUCTR2010-020448-37-NL21/12/201116/09/2010Randomized placebo-controlled multicenter exploratory Phase IIA study to assess the safety and efficacy of PEG-liposomal prednisolone sodium phosphate (Nanocort) in subjects with active ulcerative colitis.Randomized placebo-controlled multicenter exploratory Phase IIA study to assess the safety and efficacy of PEG-liposomal prednisolone sodium phosphate (Nanocort) in subjects with active ulcerative colitis. Active Ulcerative Colitis
MedDRA version: 14.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PEG-liposomal prednisolone sodium phosphate
Product Code: Nanocort
INN or Proposed INN: Prednisolone Sodium Phosphate
Other descriptive name: PREDNISOLONE SODIUM PHOSPHATE
Enceladus PharmaceuticalsNULLNot RecruitingFemale: yes
Male: yes
20Phase 2Belgium;Netherlands
4JPRN-UMIN0000053582011/04/0101/04/2011Rapid LeukocyAPheresis InDuction for Ulcerative Colitis ulcerative colitisLCAP is determined to apply if patient does not obtain a significant improvement (higher than 50%) in spite of recieving sufficient steroid therapy (higher than 30mg/day of prednisolone) for 3 days.
LCAP is determined to apply if patient does not obtain a significant improvement (higher than 50%) in spite of recieving sufficient steroid therapy (higher than 30mg/day of prednisolone) for 14 days.
Lower Gastroenterology, Hyogo College of MedicineDepartment of Gastroenterology, Osaka City University and Department of Gastroenterology, Osaka Medical CollegeComplete: follow-up complete12years-old81years-oldMale and Female40Phase 2,3Japan
5EUCTR2010-020448-37-BE10/12/201022/12/2010Randomized placebo-controlled multicenter exploratory Phase IIA study to assess the safety and efficacy of PEG-liposomal prednisolone sodium phosphate (Nanocort) in subjects with active ulcerative colitis.Randomized placebo-controlled multicenter exploratory Phase IIA study to assess the safety and efficacy of PEG-liposomal prednisolone sodium phosphate (Nanocort) in subjects with active ulcerative colitis. Active Ulcerative Colitis
MedDRA version: 14.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PEG-liposomal prednisolone sodium phosphate
Product Code: Nanocort
INN or Proposed INN: Prednisolone Sodium Phosphate
Other descriptive name: PREDNISOLONE SODIUM PHOSPHATE
Enceladus PharmaceuticalsNULLNot RecruitingFemale: yes
Male: yes
20Phase 2Belgium;Netherlands
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2008-005903-25-BG23/04/201014/04/2010Exploratory, open-label study to demonstrate efficacy, safety and tolerability of SC12267 (35 mg) in patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis)Exploratory, open-label study to demonstrate efficacy, safety and tolerability of SC12267 (35 mg) in patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis) inflammatory bowel disease (Crohn’s disease and ulcerative colitis)
MedDRA version: 12.0Level: LLTClassification code 10021973Term: Inflammatory bowel disease NOS
Product Name: SC12267
Product Code: SC12267
Trade Name: Prednisolon Jenapharm
INN or Proposed INN: Prednisolon
Trade Name: Prednisolon Jenapharm
INN or Proposed INN: Prednisolon
Trade Name: Prednisolon Jenapharm
INN or Proposed INN: Prednisolon
4SC AGNULLNot RecruitingFemale: yes
Male: yes
24Germany;Bulgaria
7NCT00984568November 200924/9/2009Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553)Conventional Step-Up Versus Infliximab Monotherapy in Patients With Active Moderate to Severe Ulcerative Colitis. A Randomized, Open Label, Prospective, Multicenter StudyColitis, UlcerativeBiological: Infliximab;Drug: Prednisolone;Drug: 5-aminosalicylic acid;Drug: AzathioprineMerck Sharp & Dohme Corp.NULLTerminated18 YearsN/AAll28Phase 3Germany
8EUCTR2009-010065-23-DE17/08/200914/04/2009Conventional Step-Up versus Infliximab Monotherapy in Patients with Active Moderate to Severe Ulcerative Colitis. A Randomized, Open Label, Prospective, Multicenter Study (Phase 3, Protocol No. P05553) - MUNIXConventional Step-Up versus Infliximab Monotherapy in Patients with Active Moderate to Severe Ulcerative Colitis. A Randomized, Open Label, Prospective, Multicenter Study (Phase 3, Protocol No. P05553) - MUNIX Active Moderate to Severe Ulcerative Colitis
MedDRA version: 14.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 14.1Level: LLTClassification code 10033007Term: Other ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 14.1Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 10017947 - Gastrointestinal disorders
MedDRA version: 14.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disorders
Trade Name: Remicade
INN or Proposed INN: infliximab
Other descriptive name: 100
Trade Name: Pentasa 500 mg Retardtabletten
Product Name: 5-Aminosalicylic acid (5-ASA)
INN or Proposed INN: 5-Aminosalicylic acid
Trade Name: Imurek 25mg Filmtabletten
INN or Proposed INN: azathioprine
Trade Name: Imurek 50mg Filmtabletten
INN or Proposed INN: azathioprine
Trade Name: Decortin H 1 mg
INN or Proposed INN: prednisolone
Trade Name: Decortin H 5mg
INN or Proposed INN: prednisolone
Trade Name: Decortin H 10mg
INN or Proposed INN: prednisolone
Trade Name: Decortin H 20mg
INN or Proposed INN: prednisolone
Trade Name: Decortin H 50 mg
INN or Proposed INN: prednisolone
Essex Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
Phase 3Germany
9EUCTR2008-005903-25-DE08/01/200903/11/2008Exploratory, open-label study to demonstrate efficacy, safety and tolerability of SC12267 (35 mg) in patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis)Exploratory, open-label study to demonstrate efficacy, safety and tolerability of SC12267 (35 mg) in patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis) inflammatory bowel disease (Crohn’s disease and ulcerative colitis)
MedDRA version: 12.0Level: LLTClassification code 10021973Term: Inflammatory bowel disease NOS
Product Name: SC12267
Product Code: SC12267
Trade Name: Prednisolon Jenapharm
INN or Proposed INN: Prednisolon
Trade Name: Prednisolon Jenapharm
INN or Proposed INN: Prednisolon
Trade Name: Prednisolon Jenapharm
INN or Proposed INN: Prednisolon
4SC AGNULLNot RecruitingFemale: yes
Male: yes
35Bulgaria;Germany
10EUCTR2004-005032-35-BE06/03/200723/11/2006A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis.A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis. Moderate acute ulcerative colitis.Product Name: COLAL-PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone sodium metasulphobenzoate
Product Name: Prednisolone
INN or Proposed INN: Prednisolone
Product Name: COLAL-PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone sodium metasulphobenzoate
Product Name: COLAL-PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone sodium metasulphobenzoate
Alizyme Therapeutics LimitedNULLNot RecruitingFemale: yes
Male: yes
890Hungary;Czech Republic;United Kingdom;Denmark;Belgium;Spain;Italy;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2004-005032-35-IT10/05/200619/01/2007A Phase III, Multicentre, Pan-European, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of Targeted Release Prednisolone in Treatment of Moderate, Acute Ulcerative ColitisA Phase III, Multicentre, Pan-European, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of Targeted Release Prednisolone in Treatment of Moderate, Acute Ulcerative Colitis Ulcerative colitis
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
Product Name: COLAL PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone
Product Name: COLAL PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone
Product Name: COLAL PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone
Trade Name: PREDNISOLONE
INN or Proposed INN: Prednisolone
ALIZYMENULLNot RecruitingFemale: yes
Male: yes
890Phase 3Hungary;Czech Republic;United Kingdom;Belgium;Denmark;Spain;Italy;Sweden
12NCT00299013March 20062/3/2006Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative ColitisA Multicentre, Randomised, Double Blind, Double Dummy, Active Comparator Controlled, Parallel Group Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative ColitisUlcerative ColitisDrug: COLAL-PRED®;Drug: PrednisoloneAlizymeNULLCompleted18 Years75 YearsBoth796Phase 3Australia;Belgium;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;South Africa;Spain;Sweden;United Kingdom
13EUCTR2004-005032-35-SE17/11/200514/09/2005A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis.A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis. Moderate acute ulcerative colitis.Product Name: COLAL-PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone sodium metasulphobenzoate
Product Name: Prednisolone
INN or Proposed INN: Prednisolone
Product Name: COLAL-PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone sodium metasulphobenzoate
Product Name: COLAL-PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone sodium metasulphobenzoate
Alizyme Therapeutics LimitedNULLNot RecruitingFemale: yes
Male: yes
890Hungary;Czech Republic;United Kingdom;Belgium;Denmark;Spain;Italy;Sweden
14EUCTR2004-005032-35-CZ04/11/200516/09/2005A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis.A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis. Moderate acute ulcerative colitis.Product Name: COLAL-PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone sodium metasulphobenzoate
Product Name: Prednisolone
INN or Proposed INN: Prednisolone
Product Name: COLAL-PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone sodium metasulphobenzoate
Product Name: COLAL-PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone sodium metasulphobenzoate
Alizyme Therapeutics LimitedNULLNot RecruitingFemale: yes
Male: yes
890Hungary;United Kingdom;Czech Republic;Belgium;Denmark;Spain;Italy;Sweden
15EUCTR2004-005032-35-DK24/10/200504/10/2005A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis.A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis. Moderate acute ulcerative colitis.Product Name: COLAL-PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone sodium metasulphobenzoate
Product Name: Prednisolone
INN or Proposed INN: Prednisolone
Product Name: COLAL-PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone sodium metasulphobenzoate
Product Name: COLAL-PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone sodium metasulphobenzoate
Alizyme Therapeutics LimitedNULLNot RecruitingFemale: yes
Male: yes
890Hungary;Czech Republic;United Kingdom;Belgium;Denmark;Spain;Italy;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2004-005032-35-HU24/10/200522/09/2005A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis.A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis. Moderate acute ulcerative colitis.Product Name: COLAL-PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone sodium metasulphobenzoate
Trade Name: Prednisolone
Product Name: Prednisolone
INN or Proposed INN: Prednisolone
Product Name: COLAL-PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone sodium metasulphobenzoate
Product Name: COLAL-PRED
Product Code: ATL-2502
INN or Proposed INN: Prednisolone sodium metasulphobenzoate
Alizyme Therapeutics LimitedNULLNot RecruitingFemale: yes
Male: yes
890Hungary;Czech Republic;United Kingdom;Belgium;Denmark;Spain;Italy;Sweden